-
An Extension Study Of Lirentelimab In Eosinophilic Gastritis And/or Eosinophilic Duodenitis (Formerly Referred To As Eosinophilic Gastroenteritis)
Scottsdale/Phoenix, AZ; Rochester, MN
The purpose of this study is to generate open-label, longer-term safety, tolerability, and effectiveness follow-up data in patients with EG and/or EoD who completed Study AK002-016 or Study AK002-012.
-
A Study To Evaluate The Safety, Tolerability, And Activity Of Escalating Doses Of AK002 In Patients With Eosinophilic Gastritis (EG) And/or Eosinophilic Gastroenteritis (EGE)
Rochester, MN
The purpose of this study is to evaluate the safety, tolerability, and activity of escalating doses of AK002 in patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE).
-
A Study To Evaluate The Safety And Effectiveness Of AK002 In Patients With Active Eosinophilic Gastritis
Scottsdale/Phoenix, AZ; Rochester, MN
The purpose of this study is to evaluate the effectiveness and safety of 4 doses of AK002 in patients with moderate to severe EG and/or EGE when compared to placebo.
-
Minimal Risk Registry of Endoscopic Image and Pathology Correlation for Fujiflim
Jacksonville, FL; Rochester, MN
The purpose of this study is to see if advanced endoscopic imaging may be helpful to accurately distinguish pathological tissue from normal tissue and guide therapy of endoscopically identified pathology.
-
Celiac Disease Registry
Rochester, MN
The purpose of this study is to develop a resource (bank) of biospecimens (blood, tissue, stool) and data collected from individuals with known or suspected gluten enteropathy, including celiac disease (CD) and dermatitis herpetiformis (DH). Other enteropathies will also be included: collagenous sprue, idiopathic sprue, lymphocytic enterocolitis, idiopathic enteropathies, collagenous gastritis, Whipple’s disease, and other miscellaneous inflammatory disorders of the small intestine. This resource will be invaluable in answering the important questions outlined above and other future unanswered questions.